# Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects

> **NCT04044339** · PHASE1 · COMPLETED · sponsor: **Theravance Biopharma** · enrollment: 56 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** TD-5202
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04044339
- **Lead sponsor:** Theravance Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-08
- **Primary completion:** 2019-11-27
- **Final completion:** 2019-11-27
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2021-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04044339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04044339, "Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04044339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*